StarryGene, a biotech company specializing in gene therapy and based in Hefei, China, has announced that the first patient has been dosed in a Phase I clinical study for its gene therapy XMVA09 injection, which is designed to treat wet age-related macular degeneration (wAMD).
XMVA09 is positioned as the world’s only gene therapy that combines a dual antibody target with an intravitreal injection approach. The therapy utilizes an adeno-associated virus (AAV) gene vector carrying genes for VEGF-A and Ang-2 bispecific antibodies. It is administered directly to retinal pigment epithelial (RPE) cells via an intravitreal injection, expressing therapeutic proteins aimed at providing a long-term treatment for wAMD. Initial results from the Phase III study have indicated that XMVA09 is safe, reliable, and well-tolerated, meeting the initial research expectations for evaluating its therapeutic effects.- Flcube.com
